Corrigendum

Corrigendum to “Chaperone-Mediated Autophagy Markers LAMP2A and HSC70 Are Independent Adverse Prognostic Markers in Primary Resected Squamous Cell Carcinomas of the Lung”

Tereza Losmanová, Félice A. Janser, Magali Humbert, Igor Tokarchuk, Anna M. Schläflı, Christina Neppl, Ralph A. Schmid, Mario P. Tschan, Rupert Langer, and Sabina Berezowska

1Institute of Pathology, University of Bern, Bern 3008, Switzerland
2Graduate School for Cellular and Biomedical Sciences, Bern 3012, Switzerland
3Division of General Thoracic Surgery, Inselspital University Hospital Bern, Bern 3010, Switzerland
4Department of Biomedical Research (DBMR), University of Bern, Bern 3008, Switzerland
5Institute of Pathology and Molecular Pathology, Kepler University Hospital, Johannes Kepler University Linz, 4021 Linz, 4040 Linz, Austria
6Institut de Pathologie, Centre HospitalierUniversitaire Vaudois et Université de Lausanne, Lausanne 1011, Switzerland

Correspondence should be addressed to Sabina Berezowska; sabina.berezowska@chuv.ch

Received 10 November 2021; Accepted 10 November 2021; Published 30 November 2021

Copyright © 2021 Tereza Losmanová et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

In the article titled “Chaperone-Mediated Autophagy Markers LAMP2A and HSC70 Are Independent Adverse Prognostic Markers in Primary Resected Squamous Cell Carcinomas of the Lung” [1], the authors identified an error in the name of the manufacturer of the antibody mentioned in Materials and Methods. The following should be corrected from

“LAMP2A (Novus Biologicals, Zug, Switzerland, rabbit polyclonal, #NB600-1384)
HSC70 (LabForcembl, Nunningen, Switzerland, rabbit polyclonal, #PM0045)”

to

“LAMP2A (Abcam, Cambridge, UK, rabbit polyclonal, ab18528)
HSC70 (Thermo Fisher Scientific, Waltham, MA, USA, mouse monoclonal, MA3-014)”

References